Treatment with low-dose RAD001 (0.01 mg/kg) reduced the density of CD31+ tumor vessels (Figure 3B) and induced an increase in pericyte coverage of tumor vessels, as measured by CD31/α-SMA costaining in tumors (Figure 3C), indicating an improvement in vessel maturation. This evidence concerns the gene ACTA1 and neoplasm.